All Articles

Shannon Miller – 7-time Olympic medalist and ovarian cancer survivor – encourages navigators at the eighth annual meeting of AONN+ saying just as an athlete doesn’t win an Olympic gold medal alone, a patient doesn’t beat cancer alone. It takes a team to succeed, and navigators are a vital part of that team.

Although there historically has been a gap in the literature regarding the key areas that measure the success of navigation programs, the Academy of Oncology Nurse & Patient Navigators (AONN+) evidence-based oncology navigation metrics are making strides in closing that gap.

Navigating patients through the complexities of breast cancer is a unique challenge, but cross-collaboration between breast patient navigators and oncology nurse navigators can make a world of difference in improving patient care.

In front of an enthusiastic audience of nearly 1000 peers and colleagues at the Eighth Annual Navigation & Survivorship Conference, Ms Mulderrig was presented the ONE Award by the Academy of Oncology Nurse & Patient Navigators Cofounder and Program Director Lillie D. Shockney, who articulated the importance of recognizing those in the field exemplifying excellence in oncology nursing.

In today’s healthcare environment, organizations are focusing on quality, outcomes, and evidence-based practice. In this installment of Evidence into Practice, the authors discuss these important qualities in an effective navigation program.

Patient and nurse navigators play an important role in the care of patients from screening through treatment and into survivorship.

In a rural outpatient cancer center affiliated with a nonprofit community hospital, cancer patients prescribed oral chemotherapy receive written and verbal education on the oral chemotherapy agent from the oncology nurse navigator.

The Academy of Oncology Nurse & Patient Navigators and Sarah Cannon, the Cancer Institute of HCA Healthcare, have announced their partnership in a pilot validation study of the 35 AONN+ standardized metrics for navigation programs.

Oncology navigation has made great strides in improving cancer care, including access to quality care, for nearly 3 decades. Navigation programs are well established for most patient populations with solid organ tumors, but less so within the patient populations with liquid cancers. I am pleased to report that this is changing, and it is wonderful to see.

A recent survey of patients with myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia, has identified a strong association between symptom burden and medical disability leave.